TABLE 1 | A selection of peptide-based vaccines at various stages of development
From the following article:
More than one reason to rethink the use of peptides in vaccine design
Anthony W. Purcell, James McCluskey & Jamie Rossjohn
Nature Reviews Drug Discovery 6, 404-414 (May 2007)
doi:10.1038/nrd2224
| Company (url) | Vaccine | Notes |
|---|---|---|
| Launched peptide-based vaccines | ||
| Pfizer (http://www.pfizer.com) | Immunocastration of pigs and companion animals, Improvac | Gonadotropin-releasing hormone (GnRH)-based vaccine to remove boar taint |
| Phase III | ||
| Sanofi Pasteur (http://www.sanofipasteur.com) | Gastric cancer vaccine | Based on gastrin-related peptides |
| Phase II/III | ||
| Avant Immunotherapeutics (http://www.avantimmune.com) | Hypolipidaemic, CETi-1 vaccine | Targets cholesteryl ester transfer protein |
| Bionor Immuno (http://www.bionorimmuno.com) | AIDS vaccine, Vacc-4X | HIV p24 peptide |
| Phase II | ||
| Novartis (http://www.novartis.com) | Allergy Vaccine | Anti-asthmatic |
| Immune Response Corporation (http://www.imnr.com) | NeuroVax | Multiple sclerosis (MS) treatment consisting of three T-cell receptor (TCR) peptides (BV5S2, BV6S5 and BV13S1) that represent immunogenic regions from TCRs expressed by pathogenic T cells in over 90% of patients with MS |
| Intercell (http://www.intercell.com) | IC-41 | Targets hepatitis C virus |
| Alteris Therapeutics (http://www.alteristhera.com) | ALT-110 | Peptide based on the epidermal growth factor receptor type III deletion mutant (EGFRvIII) cancer antigen that is currently being studied in a Phase II clinical trial for brain cancer and a Phase I clinical trial for various other cancers |
| Neurocrine Biosciences (http://www.neurocrine.com) | NBI-6024 | Altered peptide ligand based on insulin for treatment of type I diabetes |
| Memorial Sloan–Kettering Cancer Center (http://www.mskcc.org) | CMLVAX100 | Targets leukaemia by using the BCR–ABL junction peptide |
| Pharmexa (http://www.pharmexa.com) | GemVax | Vaccine for treatment of colorectal and gastric cancers with the microsatellite instability (MSI) phenotype. The vaccine consists of peptides reflecting frameshift-mutated transforming growth factor- receptor 2 (TGFR2) and BCL-2-associated X protein (BAX) protein sequences frequently found in MSI tumours |
| Pharmexa | GV1001 | Vaccine based on a combination of telomerase vaccine and p21 Ras peptides for treatment of pancreatic, colorectal and lung cancer |
| Sanofi Pasteur | Canarypox-based vaccine (ALVAC) plus peptide boost | ALVAC AIDS vaccine plus peptides, ALVAC-MAGE1,3 plus peptides, and ALVAC-gp100 plus peptides for skin cancer |
| Phase I | ||
| Antigenics (http://www.antigenics.com) | AG-707 | Vaccine against genital herpes caused by herpes simplex virus-2 (HSV-2). Based on AG-702, an earlier vaccine that contained a single antigen. It consists of a recombinant human heat-shock protein (HSP) complexed with 32 synthetic peptides from HSV-2 proteins |
| Crucell and Pevion (http://www.crucell.com; http://www.pevion.com) | Malaria vaccines | Based on two synthetic peptides, which mimic the native structure of important antigens of the malaria parasite. |
| GSK (http://www.gsk.com) | Breast cancer vaccine, prostate cancer vaccine | HER-2/neu (also known as ERBB2)-peptide microspheres that target breast cancer and microspheres containing proprietary prostate-antigen-derived peptides |
| DOR Biopharma (http://www.dorbiopharma.com) | RiVax | Based on ricin-toxin-derived peptides |
| Millenium Biologix (http://www.millenium-biologix.com) | Pseudomonas vaccine, Cytovaxine | Consensus sequence peptide vaccine used to prevent Pseudomonas aeruginosa infection, which is among the leading causes of hospital-acquired pneumonia |
| Wyeth (http://www.wyeth.com) | HIV-CTL multi-epitope peptide vaccine formulated with RC529-5E and GM-CSF | Synthetic peptide, multi-epitope vaccine for AIDS |
| National Cancer Institute (Rosenberg laboratory) (http://www.cancer.gov) | Designer peptide vaccine | Designer peptide vaccine based on gp100 for treatment of melanoma |
| Generex (http://www.generex.com) | Invariant-chain peptide fusions | Vaccines targeting infectious diseases (HIV, H5 influenza, Vaccinia) and cancer (melanoma, HER-2/Neu) |
| Ludwig Institute for Cancer Research (http://www.licr.org) | Peptide-based vaccines for an array of cancers | Based on testes cancer class of antigens and epitopes mapped from them. For example, NY-ESO-1 and MAGE |
| Preclinical development | ||
| Crucell and Bachem (http://www.bachem.com) | Various vaccines | For treating Alzheimer's disease, breast cancer, melanoma |
| MDM Group Inc. (http://www.mdmgroupinc.com/biodefense.php) | Smallpox vaccine | Vaccine is based on the Maksyutov Antigenic Peptide technology platform |
| DOR Biopharma | BT-VACC | Targets botulinum toxin |
| Immunotope (http://www.immunotope.com) | Ovarian and colon cancer related peptide cocktails that target heterogeneously expressed antigens | For treating colon cancer, ovarian cancer |
| Mymetics and Pevion (http://www.mymetics.com) | HIV vaccine | HIV gp41-derived peptides fused to a virosome |
| Neovacs (http://neovacs.com) | E7 toxoid | For treating cervix cancer |
| Pepscan systems (http://www.pepscan.nl) | Prostate cancer vaccine | Anti-gonadotropin-releasing hormone (GnRH) |
| Pevion | Breast cancer vaccine | Based on HER-2/Neu peptides fused onto a virosome |
| Prana Biotech (http://www.pranabio.com) | Vaccine for Alzheimer's disease, PBT-2 | Targets -amyloid |
| Vaccine Solutions (http://www.vaccine-solutions.com.au) | Vaccines targeting infection diseases | Targets cytomegalovirus, Streptococcus |
Download file
If the slide opens in your browser, select "File > Save As" to save it.
